The Experts below are selected from a list of 213 Experts worldwide ranked by ideXlab platform

Philip E Castle - One of the best experts on this subject based on the ideXlab platform.

  • comparison of linear array and line blot assay for detection of human papillomavirus and diagnosis of cervical precancer and cancer in the atypical squamous cell of undetermined significance and low grade squamous intraepithelial lesion triage study
    Journal of Clinical Microbiology, 2008
    Co-Authors: Philip E Castle, Patti E Gravitt, Diane Solomon, Cosette M Wheeler, Mark Schiffman
    Abstract:

    We evaluated Linear Array (LA), a newly commercialized PGMY09/11 L1 consensus primer PCR test that detects 37 human papillomavirus (HPV) genotypes by reverse line blot hybridization, for the detection of individual HPV genotypes and Carcinogenic HPV and its clinical performance for detecting 2-year cumulative cervical precancer and cancer using archived specimens from the Atypical Squamous Cell of Undetermined Significance (ASCUS) and Low-Grade Squamous Intraepithelial Lesion Triage Study. LA testing was conducted on enrollment specimens from women referred because of an ASCUS Pap test. To gauge the performance of the new test, the results were compared to those of its prototype predecessor assay, Line Blot Assay (LBA), restricted to paired results (n = 3,335). LA testing was done masked to LBA results and clinical outcomes. The results of LA and LBA testing were compared for detection of Carcinogenic HPV and clinical outcomes of cervical precancer and cancer. Overall, 50% and 55% of the women tested positive for Carcinogenic HPV by LBA and LA, respectively (P < 0.0001). The percent agreement for Carcinogenic HPV detection was 88%, percent positive agreement was 80%, and kappa was 0.76 for detection of Carcinogenic HPV by the two assays. There was a significant increase in detection by LA for most of the 37 HPV genotypes targeted by both assays, including for 13 of 14 Carcinogenic HPV genotypes. LA detected more multiple-genotype infections for all HPV genotypes among HPV-positive women (P < 0.0001) and for Carcinogenic HPV genotypes among Carcinogenic-HPV-positive women (P < 0.0001). LA was more sensitive (92.3% versus 87.1%; P = 0.003) and less specific (48.2% versus 54.0%; P < 0.0001) than LBA for 2-year cumulative cervical precancer and cancer as diagnosed by the Pathology Quality Control Group. In conclusion, we found LA to be a promising assay for the detection of HPV genotypes and Carcinogenic HPV, and it may be clinically useful for the detection of cervical precancer and cancer in women with equivocal cytology.

  • a cross sectional study of a prototype Carcinogenic human papillomavirus e6 e7 messenger rna assay for detection of cervical precancer and cancer
    Clinical Cancer Research, 2007
    Co-Authors: Philip E Castle, Francisco A R Garcia, Amy L Mitchell, Janel Dockter, Cristina Giachetti, Mary Kay Mccormick, Blair E Holladay, Daniel P Kolk
    Abstract:

    Purpose: To evaluate Carcinogenic human papillomavirus (HPV) mRNA for E6 and E7 mRNA detection on clinical specimens to identify women with cervical precancer and cancer. Experimental Design: We evaluated a prototype assay that collectively detects oncogenes E6/E7 mRNA for 14 Carcinogenic HPV genotypes on a sample of liquid cytology specimens ( n = 531), masked to clinical data and to the presence of HPV genotypes detected by PGMY09/11 L1 consensus primer PCR assay. Results: We found an increasing likelihood of testing positive for Carcinogenic HPV E6/E7 mRNA with increasing severity of cytology ( P Trend < 0.0001) and histology ( P Trend < 0.0001), with 94% of cervical intraepithelial neoplasia grade 3 (CIN3) histology cases (46 of 49) and all five cancer cases testing positive for Carcinogenic HPV E6/E7 mRNA. Overall, fewer specimens tested positive for Carcinogenic HPV E6/E7 mRNA than for Carcinogenic HPV DNA ( P < 0.0001, McNemar's χ2 test), especially in women with Carcinogenic HPV E6/E7 mRNA improved the association of positive test results with cervical precancer and cancer by reducing the number of test positives in women without precancer without reducing clinical sensitivity for cervical precancer and cancer compared with detection of Carcinogenic HPV E6/E7 mRNA using a lower positive cutpoint by the same assay and with detection of Carcinogenic HPV DNA. Conclusions: We found that Carcinogenic HPV E6/E7 mRNA is a potentially useful biomarker for detection of cervical precancer and cancer and warrants further evaluation.

  • Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens
    Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a >or=94% total agreement and kappa values of >or=0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a >or=74% total agreement, >or=0.62 unweighted kappa, and >or=0.75 linearly weighted kappa between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and kappa of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs.

  • mouthwash as a low cost and safe specimen transport medium for human papillomavirus dna testing of cervicovaginal specimens
    Cancer Epidemiology Biomarkers & Prevention, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a ≥94% total agreement and κ values of ≥0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a ≥74% total agreement, ≥0.62 unweighted κ , and ≥0.75 linearly weighted κ between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and κ of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs. (Cancer Epidemiol Biomarkers Prev 2007;16(4):840–3)

  • human papillomavirus testing following loop electrosurgical excision procedure identifies women at risk for posttreatment cervical intraepithelial neoplasia grade 2 or 3 disease
    Cancer Epidemiology Biomarkers & Prevention, 2006
    Co-Authors: Aimee R Kreimer, Mark Schiffman, Diane Solomon, Cosette M Wheeler, Richard Guido, Sholom Wacholder, Jose Jeronimo, Philip E Castle
    Abstract:

    Background: Loop electrosurgical excision procedure (LEEP) is the predominant treatment for cervical intraepithelial neoplasia grade 2 or 3 (CIN2+) in the United States, yet following treatment ∼10% of women are diagnosed again with CIN2+, necessitating close follow-up of such patients. Methods: Surveillance strategies using cytology and/or human papillomavirus (HPV) testing were compared among women who underwent LEEP ( n = 610) in the Atypical Squamous Cells of Undetermined Significance (ASCUS) Low-Grade Squamous Intraepithelial Lesion (LSIL) Triage Study. Cervical specimens, collected at 6-month visits for 2 years, were used for cytology, Hybrid Capture 2 (HC2) detection of Carcinogenic HPVs, and PCR for genotyping of Carcinogenic and nonCarcinogenic HPV types. At exit, women had colposcopy for safety and disease ascertainment. Results: At the visit post-LEEP (median time: 4.5 months after LEEP), 36.9% [95% confidence interval (95% CI), 32.7-41.1%] of women were positive for Carcinogenic HPV by PCR and 33.7% (95% CI, 29.7-37.9) had ASCUS or more severe (ASCUS+) cytology. The overall 2-year cumulative incidence of histologically confirmed posttreatment CIN2+ was 7.0%; this could be further stratified by the HPV risk category detected at the 6-month visit after LEEP. The 2-year risk associated with HPV16 positivity was 37.0%, significantly higher than for other Carcinogenic HPV types (10.8%, P < 0.001), nonCarcinogenic types (1.5%, P < 0.001), or testing HPV negative (0%). Post-LEEP cytology (using a positive threshold of ASCUS+) was 78.1% (95% CI, 60.0-90.7%) sensitive for detection of posttreatment CIN2+. By comparison, PCR for Carcinogenic HPV and combination testing (using a positive result from Carcinogenic HPV testing or cytology as the test threshold with HPV-negative ASCUS not referred) were significantly more sensitive (96.9% for each, P = 0.03); HC2 alone was nonsignificantly more sensitive (90.6%, P = 0.3). Specificity was similar for ASCUS+ cytology (69.1%, 95% CI, 64.6-73.3%) and PCR for Carcinogenic HPV (67.1%, P = 0.5), yet was lower for HC2 (63.8%, P = 0.048) and combination testing (62.9%, P = 0.02). Conclusion: Women who tested positive after LEEP for Carcinogenic HPV types, especially HPV16, had high risk of subsequent CIN2+. HPV-based detection methods, alone or in combination with cytology, may be useful to incorporate in post-LEEP management strategies. (Cancer Epidemiol Biomarkers Prev 2006;15(5):908–14)

Dong-pyo Kim - One of the best experts on this subject based on the ideXlab platform.

  • Micro-total envelope system with silicon nanowire separator for safe Carcinogenic chemistry
    Nature Communications, 2016
    Co-Authors: Ajay K. Singh, Niraj K. Vishwakarma, Seungwook Jang, Kyoung-ik Min, Dong-pyo Kim
    Abstract:

    Exploration and expansion of the chemistries involving toxic or Carcinogenic reagents are severely limited by the health hazards their presence poses. Here, we present a micro-total envelope system (μ-TES) and an automated total process for the generation of the Carcinogenic reagent, its purification and its utilization for a desired synthesis that is totally enveloped from being exposed to the carcinogen. A unique microseparator is developed on the basis of SiNWs structure to replace the usual exposure-prone distillation in separating the generated reagent. Chloromethyl methyl ether chemistry is explored as a Carcinogenic model in demonstrating the efficiency of the μ-TES that is fully automated so that feeding the ingredients for the generation is all it takes to produce the desired product. Syntheses taking days can be accomplished safely in minutes with excellent yields, which bodes well for elevating the Carcinogenic chemistry to new unexplored dimensions. Carcinogenic compounds present difficulties in synthesis not just during reaction but perhaps especially during purification. Here, the authors report a microfluidic device for the use of Carcinogenic chloromethyl methyl ether that includes a silicon nanowire separator allowing isolated, automated purification.

  • Micro-total envelope system with silicon nanowire separator for safe Carcinogenic chemistry
    Nature communications, 2016
    Co-Authors: Ajay Singh, Niraj K. Vishwakarma, Seungwook Jang, Kyoung-ik Min, Dong-pyo Kim
    Abstract:

    Exploration and expansion of the chemistries involving toxic or Carcinogenic reagents are severely limited by the health hazards their presence poses. Here, we present a micro-total envelope system (μ-TES) and an automated total process for the generation of the Carcinogenic reagent, its purification and its utilization for a desired synthesis that is totally enveloped from being exposed to the carcinogen. A unique microseparator is developed on the basis of SiNWs structure to replace the usual exposure-prone distillation in separating the generated reagent. Chloromethyl methyl ether chemistry is explored as a Carcinogenic model in demonstrating the efficiency of the μ-TES that is fully automated so that feeding the ingredients for the generation is all it takes to produce the desired product. Syntheses taking days can be accomplished safely in minutes with excellent yields, which bodes well for elevating the Carcinogenic chemistry to new unexplored dimensions.

Janet Kornegay - One of the best experts on this subject based on the ideXlab platform.

  • Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens
    Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a >or=94% total agreement and kappa values of >or=0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a >or=74% total agreement, >or=0.62 unweighted kappa, and >or=0.75 linearly weighted kappa between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and kappa of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs.

  • mouthwash as a low cost and safe specimen transport medium for human papillomavirus dna testing of cervicovaginal specimens
    Cancer Epidemiology Biomarkers & Prevention, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a ≥94% total agreement and κ values of ≥0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a ≥74% total agreement, ≥0.62 unweighted κ , and ≥0.75 linearly weighted κ between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and κ of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs. (Cancer Epidemiol Biomarkers Prev 2007;16(4):840–3)

Francisco A R Garcia - One of the best experts on this subject based on the ideXlab platform.

  • a cross sectional study of a prototype Carcinogenic human papillomavirus e6 e7 messenger rna assay for detection of cervical precancer and cancer
    Clinical Cancer Research, 2007
    Co-Authors: Philip E Castle, Francisco A R Garcia, Amy L Mitchell, Janel Dockter, Cristina Giachetti, Mary Kay Mccormick, Blair E Holladay, Daniel P Kolk
    Abstract:

    Purpose: To evaluate Carcinogenic human papillomavirus (HPV) mRNA for E6 and E7 mRNA detection on clinical specimens to identify women with cervical precancer and cancer. Experimental Design: We evaluated a prototype assay that collectively detects oncogenes E6/E7 mRNA for 14 Carcinogenic HPV genotypes on a sample of liquid cytology specimens ( n = 531), masked to clinical data and to the presence of HPV genotypes detected by PGMY09/11 L1 consensus primer PCR assay. Results: We found an increasing likelihood of testing positive for Carcinogenic HPV E6/E7 mRNA with increasing severity of cytology ( P Trend < 0.0001) and histology ( P Trend < 0.0001), with 94% of cervical intraepithelial neoplasia grade 3 (CIN3) histology cases (46 of 49) and all five cancer cases testing positive for Carcinogenic HPV E6/E7 mRNA. Overall, fewer specimens tested positive for Carcinogenic HPV E6/E7 mRNA than for Carcinogenic HPV DNA ( P < 0.0001, McNemar's χ2 test), especially in women with Carcinogenic HPV E6/E7 mRNA improved the association of positive test results with cervical precancer and cancer by reducing the number of test positives in women without precancer without reducing clinical sensitivity for cervical precancer and cancer compared with detection of Carcinogenic HPV E6/E7 mRNA using a lower positive cutpoint by the same assay and with detection of Carcinogenic HPV DNA. Conclusions: We found that Carcinogenic HPV E6/E7 mRNA is a potentially useful biomarker for detection of cervical precancer and cancer and warrants further evaluation.

  • Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens
    Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a >or=94% total agreement and kappa values of >or=0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a >or=74% total agreement, >or=0.62 unweighted kappa, and >or=0.75 linearly weighted kappa between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and kappa of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs.

  • mouthwash as a low cost and safe specimen transport medium for human papillomavirus dna testing of cervicovaginal specimens
    Cancer Epidemiology Biomarkers & Prevention, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a ≥94% total agreement and κ values of ≥0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a ≥74% total agreement, ≥0.62 unweighted κ , and ≥0.75 linearly weighted κ between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and κ of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs. (Cancer Epidemiol Biomarkers Prev 2007;16(4):840–3)

Amy L Mitchell - One of the best experts on this subject based on the ideXlab platform.

  • a cross sectional study of a prototype Carcinogenic human papillomavirus e6 e7 messenger rna assay for detection of cervical precancer and cancer
    Clinical Cancer Research, 2007
    Co-Authors: Philip E Castle, Francisco A R Garcia, Amy L Mitchell, Janel Dockter, Cristina Giachetti, Mary Kay Mccormick, Blair E Holladay, Daniel P Kolk
    Abstract:

    Purpose: To evaluate Carcinogenic human papillomavirus (HPV) mRNA for E6 and E7 mRNA detection on clinical specimens to identify women with cervical precancer and cancer. Experimental Design: We evaluated a prototype assay that collectively detects oncogenes E6/E7 mRNA for 14 Carcinogenic HPV genotypes on a sample of liquid cytology specimens ( n = 531), masked to clinical data and to the presence of HPV genotypes detected by PGMY09/11 L1 consensus primer PCR assay. Results: We found an increasing likelihood of testing positive for Carcinogenic HPV E6/E7 mRNA with increasing severity of cytology ( P Trend < 0.0001) and histology ( P Trend < 0.0001), with 94% of cervical intraepithelial neoplasia grade 3 (CIN3) histology cases (46 of 49) and all five cancer cases testing positive for Carcinogenic HPV E6/E7 mRNA. Overall, fewer specimens tested positive for Carcinogenic HPV E6/E7 mRNA than for Carcinogenic HPV DNA ( P < 0.0001, McNemar's χ2 test), especially in women with Carcinogenic HPV E6/E7 mRNA improved the association of positive test results with cervical precancer and cancer by reducing the number of test positives in women without precancer without reducing clinical sensitivity for cervical precancer and cancer compared with detection of Carcinogenic HPV E6/E7 mRNA using a lower positive cutpoint by the same assay and with detection of Carcinogenic HPV DNA. Conclusions: We found that Carcinogenic HPV E6/E7 mRNA is a potentially useful biomarker for detection of cervical precancer and cancer and warrants further evaluation.

  • Mouthwash as a Low-Cost and Safe Specimen Transport Medium for Human Papillomavirus DNA Testing of Cervicovaginal Specimens
    Cancer epidemiology biomarkers & prevention : a publication of the American Association for Cancer Research cosponsored by the American Society of Pre, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a >or=94% total agreement and kappa values of >or=0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a >or=74% total agreement, >or=0.62 unweighted kappa, and >or=0.75 linearly weighted kappa between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and kappa of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs.

  • mouthwash as a low cost and safe specimen transport medium for human papillomavirus dna testing of cervicovaginal specimens
    Cancer Epidemiology Biomarkers & Prevention, 2007
    Co-Authors: Philip E Castle, Attila T. Lorincz, Mark Sadorra, Francisco A R Garcia, Allison Cullen, Amy L Mitchell, Denise Whitby, Ronald Chuke, Janet Kornegay
    Abstract:

    The usefulness of mouthwash as a transport medium for cervical specimens for Carcinogenic human papillomavirus (HPV) DNA testing has not been evaluated. Two cervical specimens were collected from each of 34 patients, with one placed in mouthwash (Scope, Proctor and Gamble, Inc.) and the other in a liquid cytology medium commonly used for HPV DNA testing in alternating order. Paired specimens were tested by a PCR assay for Carcinogenic HPV and a PCR HPV genotyping assay for 37 HPV types at 0, 3, and 6 weeks after collection; the results of the HPV genotyping assay were categorized into HPV risk groups according to cancer risk (HPV-16 > HPV-18 > other Carcinogenic HPV types > nonCarcinogenic HPV types > negative). After 4 months of storage, specimens were tested using a second, non-PCR test for Carcinogenic HPV. We observed a ≥94% total agreement and κ values of ≥0.88 between media at each time point for PCR-detected Carcinogenic HPV. We observed a ≥74% total agreement, ≥0.62 unweighted κ , and ≥0.75 linearly weighted κ between media at each time point for PCR-detected HPV cancer risk category. Finally, we observed an 88% total agreement and κ of 0.77 between media for Carcinogenic HPV detection using a second test after 4 months of storage. We suggest that mouthwash might be used as a low-cost, safe, nonflammable storage and transport medium for cervical specimens for HPV DNA testing in cervical cancer screening programs. (Cancer Epidemiol Biomarkers Prev 2007;16(4):840–3)